INSM:NSD-Insmed Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 70.67

Change

+0.14 (+0.20)%

Market Cap

USD 13.20B

Volume

1.11M

Analyst Target

USD 45.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+2.47 (+0.61%)

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

+2.21 (+0.31%)

USD 84.94B
ARGX argenx NV ADR

+2.05 (+0.33%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

-0.75 (-0.31%)

USD 31.66B
BGNE BeiGene Ltd

+3.06 (+1.68%)

USD 20.24B
UTHR United Therapeutics Corporatio..

+3.23 (+0.90%)

USD 16.18B
MRNA Moderna Inc

+0.16 (+0.40%)

USD 16.10B
RPRX Royalty Pharma Plc

+0.17 (+0.67%)

USD 15.27B
SMMT Summit Therapeutics PLC

+0.28 (+1.47%)

USD 13.67B
INCY Incyte Corporation

-0.35 (-0.50%)

USD 13.52B

ETFs Containing INSM

FCUS Pinnacle Focused Opportun.. 4.04 % 0.00 %

+0.02 (+1.25%)

USD 0.04B
CURE:AU ETFS S&P Biotech ETF 2.54 % 0.00 %

N/A

USD 0.04B
LABU Direxion Daily S&P Biotec.. 1.77 % 1.14 %

+2.05 (+1.25%)

USD 0.82B
RSSL Global X Funds 0.41 % 0.00 %

+1.00 (+1.25%)

USD 1.48B
XRS2:SW Xtrackers Russell 2000 UC.. 0.40 % 0.00 %

N/A

USD 2.22B
R2US:SW SPDR® Russell 2000 US Sm.. 0.40 % 0.00 %

N/A

USD 5.22B
ITWO Proshares Russell 2000 Hi.. 0.37 % 0.00 %

+0.50 (+1.25%)

USD 0.05B
UWM ProShares Ultra Russell20.. 0.35 % 0.95 %

+0.93 (+1.25%)

USD 0.50B
HDG ProShares Hedge Replicati.. 0.00 % 0.95 %

+0.13 (+1.25%)

USD 0.03B
IWM iShares Russell 2000 ETF 0.00 % 0.19 %

+2.29 (+1.25%)

N/A
IWO iShares Russell 2000 Grow.. 0.00 % 0.24 %

+3.48 (+1.25%)

N/A
JKJ 0.00 % 0.25 %

N/A

N/A
JKK 0.00 % 0.30 %

N/A

N/A
PTH Invesco DWA Healthcare Mo.. 0.00 % 0.60 %

+0.37 (+1.25%)

USD 0.14B
BTEC 0.00 % 0.42 %

N/A

N/A
VRTGX Vanguard Russell 2000 Gro.. 0.00 % 0.00 %

+4.50 (+1.25%)

USD 1.19B
VRTIX Vanguard Russell 2000 Ind.. 0.00 % 0.00 %

+3.12 (+1.25%)

USD 10.02B
URTY ProShares UltraPro Russel.. 0.00 % 0.95 %

+1.54 (+1.25%)

USD 0.54B
VTWG Vanguard Russell 2000 Gro.. 0.00 % 0.20 %

+2.65 (+1.25%)

USD 1.09B
VTWO Vanguard Russell 2000 Ind.. 0.00 % 0.15 %

+0.92 (+1.25%)

USD 13.09B
R2SC:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

N/A

USD 5.18B
R2US:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

N/A

USD 5.15B
XRSG:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

N/A

USD 2.22B
XRSU:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

N/A

USD 2.22B
R2US:PA SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 5.17B
XRS2:F Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

N/A

USD 1.19B
ZPRR:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 2.91B
XRS2:XETRA Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

N/A

USD 1.19B
ZPRR:XETRA SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

N/A

USD 2.91B
ISCB iShares Morningstar Small.. 0.00 % 0.00 %

+0.40 (+1.25%)

USD 0.24B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 128.04% 92% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 128.04% 92% A 94% A
Trailing 12 Months  
Capital Gain 122.65% 92% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 122.65% 92% A 94% A
Trailing 5 Years  
Capital Gain 197.68% 93% A 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 197.68% 93% A 92% A
Average Annual (5 Year Horizon)  
Capital Gain 390.85% 91% A- 96% N/A
Dividend Return 390.85% 91% A- 96% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 2,019.89% 10% F 4% F
Risk Adjusted Return 19.35% 76% C+ 52% F
Market Capitalization 13.20B 98% N/A 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.